Trials / Active Not Recruiting
Active Not RecruitingNCT06774313
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-142 | Intravenous (IV) Infusion |
| DRUG | ABBV-142 | Subcutaneous (SC) Injection |
| DRUG | Placebo | IV Infusion |
| DRUG | Placebo | SC Injection |
Timeline
- Start date
- 2025-01-22
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2025-01-14
- Last updated
- 2026-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06774313. Inclusion in this directory is not an endorsement.